Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 16:4:43.
doi: 10.1186/s40425-016-0147-8. eCollection 2016.

It's TIME for a biomarker-driven approach to cancer immunotherapy

Leisha A Emens  1
Affiliations

It's TIME for a biomarker-driven approach to cancer immunotherapy

Leisha A Emens. J Immunother Cancer. .
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer.
    Laghi L, Negri F, Gaiani F, Cavalleri T, Grizzi F, De' Angelis GL, Malesci A. Laghi L, et al. Int J Mol Sci. 2020 Dec 18;21(24):9680. doi: 10.3390/ijms21249680. Int J Mol Sci. 2020. PMID: 33353162 Free PMC article. Review.
  • State of the Art of Natural Killer Cell Imaging: A Systematic Review.
    Varani M, Auletta S, Signore A, Galli F. Varani M, et al. Cancers (Basel). 2019 Jul 9;11(7):967. doi: 10.3390/cancers11070967. Cancers (Basel). 2019. PMID: 31324064 Free PMC article. Review.
  • Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.
    Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Hirohashi Y, Furuhata T, Takemasa I, Patel P, Vora H, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Yoshino T, Taniguchi H, Bifulco C, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson E, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Marliot F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majdi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, Van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Marincola FM, Ascierto PA, Fox BA, Pagès F, Kawakami Y, Galon J. Mlecnik B, et al. Cancers (Basel). 2022 Sep 6;14(18):4346. doi: 10.3390/cancers14184346. Cancers (Basel). 2022. PMID: 36139506 Free PMC article.
  • Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
    Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Lafontaine L, Bruni D, Lanzi A, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Muşină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Fox BA, Pagès F, Galon J. Mlecnik B, et al. J Clin Oncol. 2020 Nov 1;38(31):3638-3651. doi: 10.1200/JCO.19.03205. Epub 2020 Sep 8. J Clin Oncol. 2020. PMID: 32897827 Free PMC article.

References

    1. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587–600. doi: 10.1053/j.seminoncol.2015.05.013. - DOI - PMC - PubMed
    1. Emens LA, Jaffee EM. Cancer vaccines: on the threshold of success. Cancer Biol Ther. 2003;2(Suppl1):S161–S168. doi: 10.4161/cbt.2.2.283. - DOI - PubMed
    1. Emens LA. Roadmap to a better therapeutic tumor vaccine. Intl Rev Immunol. 2006;25:415–443. doi: 10.1080/08830180600992423. - DOI - PubMed
    1. Emens LA, Silversten SC, Khleif S, Marincola FM, Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med. 2012;10:70. doi: 10.1186/1479-5876-10-70. - DOI - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Pensen DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi: 10.1056/NEJMoa1001294. - DOI - PubMed

LinkOut - more resources